Core Insights - The latest data from the Hong Kong Stock Exchange indicates that on August 18, shareholders of Deking Pharmaceutical-B (06996) deposited shares worth HKD 416 million into Standard Chartered Bank (Hong Kong), representing 9.23% of the total shareholding [1] - On July 28, Deking Pharmaceutical announced that the National Medical Products Administration (NMPA) of China has approved the use of Xivio (Selinexor) in combination with Bortezomib and Dexamethasone (XVd) for the treatment of adult patients with relapsed or refractory multiple myeloma (MM) who have received at least one prior therapy, marking a new indication for Xivio [1]

Core Insights - The increasing prevalence of multiple myeloma (MM) among the aging population in China poses significant health challenges, with a doubling of incidence and a 1.5 times increase in mortality over the past 30 years [1][3] - The five-year survival rate for MM patients in China is only 24.8%, indicating a critical need for improved diagnosis and treatment strategies [1][3] Group 1: Disease Overview - Multiple myeloma is the second most common hematological malignancy, particularly affecting individuals over 60, with 75% of cases occurring in this age group [1][3] - The disease is characterized by high heterogeneity, difficulty in treatment, and a tendency to relapse, with 70% of patients showing bone lesions at diagnosis [4][3] Group 2: Risk Factors - Genetic predisposition plays a significant role in the development of MM, with a higher incidence in individuals with a family history of hematological malignancies [2][3] - Environmental factors such as chemical exposure, radiation, chronic viral infections, and autoimmune diseases also contribute to the risk of developing MM [2][3] Group 3: Treatment Landscape - Recent advancements in treatment options include proteasome inhibitors, immunomodulatory agents, and anti-CD38 monoclonal antibodies, although relapse remains a major challenge [4][5] - Less than 10% of patients achieve long-term remission after first-line treatment, and about 25% experience early relapse [4][5] Group 4: Innovative Therapies - BCMA (B-cell maturation antigen) has emerged as a promising target for therapy, with various drug types such as antibody-drug conjugates (ADCs), CAR-T, and bispecific antibodies showing potential [6][7] - Recent studies presented at the EHA 2025 conference indicate that BCMA ADCs provide higher efficacy and longer disease control compared to standard treatments in the Chinese population [7][8] Group 5: Future Directions - The goal is to enhance treatment efficacy for newly diagnosed patients, aiming for clinical cures and improved quality of life [9] - Continuous innovation in drug development is expected to further improve treatment outcomes for MM patients [9]